Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q2 2026 › vs Q2 2025
Rhythm Pharmaceuticals (RYTM) Q2 2026 vs Q2 2025 (year over year)
Rhythm Pharmaceuticals's revenue rose $22.8M (+47%) from $48.5M in Q2 2025 to $71.3M in Q2 2026.
Rhythm Pharmaceuticals, Q2 2026: revenue $71.3M (+47% year over year), operating margin -68.1%, net loss $49.3M, operating cash flow −$9.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $71.3M | $48.5M | $22.8M | +47% |
| Net loss | $49.3M | $46.6M | $2.7M | +6% |
| Costs & expenses | $121M | $95.1M | $25.4M | +27% |
| Operating costs | $120M | $93.8M | $26.0M | +28% |
| Interest & other, net | $302K | $999K | −$697K | -70% |
| Income tax | $444K | $337K | $107K | +32% |
| Cost of revenue | $8.9M | $5.5M | $3.4M | +61% |
| Research & development | $43.4M | $42.3M | $1.1M | +3% |
| SG&A | $67.4M | $45.9M | $21.5M | +47% |
| Operating cash sources | $49.3M | $46.6M | $2.7M | +6% |
| Share-based compensation | $26.1M | $15.9M | $10.2M | +64% |
| Working capital & other | $14.1M | $7.4M | $6.7M | +89% |
| Cash used in operations | $9.2M | $23.3M | −$14.2M | -61% |
| Net loss absorbed | $49.3M | $46.6M | $2.7M | +6% |
Questions
How much did Rhythm Pharmaceuticals's revenue grow year over year in Q2 2026?
Rhythm Pharmaceuticals's revenue rose $22.8M (+47%) from $48.5M in Q2 2025 to $71.3M in Q2 2026.